Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:47:52.012Z.
Calculation as of: 2026-10-06T18:47:52.012Z.
Quote observation: 2026-10-06T18:45:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$778.24M
EV/EBITDA Ratio
10.58x
TTM Avg
147.08x
3Y Avg
35.26x
5Y Avg
24.01x
Market Cap
$786.39M
EV/EBITDA Ratio
6.63x
TTM Avg
5.45x
3Y Avg
14.30x
5Y Avg
12.03x
Market Cap
$789.07M
EV/EBITDA Ratio
N/A
TTM Avg
800.36x
3Y Avg
800.36x
5Y Avg
800.36x
Market Cap
$774.41M
EV/EBITDA Ratio
N/A
TTM Avg
14.36x
3Y Avg
6.18x
5Y Avg
6.18x
Market Cap
$800.49M
EV/EBITDA Ratio
N/A
TTM Avg
76.03x
3Y Avg
57.10x
5Y Avg
57.10x
Market Cap
$763.35M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$760.53M
EV/EBITDA Ratio
18.29x
TTM Avg
16.06x
3Y Avg
17.33x
5Y Avg
27.55x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $781.97M | N/A | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $778.24M | 10.58x | 147.08x | 35.26x | 24.01x |
| AdaptHealth Corp. (AHCO)vs › | $786.39M | 6.63x | 5.45x | 14.30x | 12.03x |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 800.36x | 800.36x | 800.36x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $774.41M | N/A | 14.36x | 6.18x | 6.18x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $800.49M | N/A | 76.03x | 57.10x | 57.10x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $763.35M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $803.29M | 5.89x | 7.11x | 8.26x | 13.78x |
| Mesa Laboratories, Inc. (MLAB)vs › | $760.53M | 18.29x | 16.06x | 17.33x | 27.55x |
| Apnimed, Inc. (APMD)vs › | $750.67M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
